The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Probucol Protects Against Adriamycin Cardiomyopathy Without Interfering With Its Antitumor Effect
Abstract
Background The usefulness of adriamycin (ADR), a potent antitumor antibiotic, is limited by the development of life-threatening cardiomyopathy and congestive heart failure. Subcellular changes leading to heart failure are suggested to be mediated by a drug-induced increase in free radicals and lipid peroxidation. In an earlier study, concurrent treatment with probucol (PROB), a lipid-lowering drug with strong antioxidant properties, was shown to offer only partial protection against ADR cardiomyopathy. The present study had two aims: to determine whether this protective effect can be improved further by extended treatment with PROB, and to determine whether PROB affects the antitumor properties of ADR. Methods and Results ADR (cumulative dose, 15 mg/kg body wt) was administered in rats in six equal injections (IP) over a period of 2 weeks. Three weeks after the end of treatment, cardiomyopathy and congestive heart failure were characterized by ascites, congested liver, depressed cardiac function, elevated left ventricular end-diastolic pressure, and myocardial cell damage. Myocardial glutathione peroxidase (GSHPx) activity was decreased and lipid peroxidation was increased. Administration of PROB (cumulative dose, 120 mg/kg body wt) in 12 equal injections (IP), before and concurrent with ADR, completely prevented these cardiomyopathic changes, normalized left ventricular function, lowered mortality, and eliminated ascites. Treatment with PROB was also accompanied by an increase in myocardial GSHPx and superoxide dismutase activities with a concomitant decrease in lipid peroxidation. Tumor regression in syngeneic DBA/2 mice inoculated with L5178Y-F9 lymphoma cells in the ADR+PROB group was significant and comparable to the ADR group. Conclusions These data show for the first time that PROB can provide complete protection against ADR cardiomyopathy without interfering with antitumor properties of the drug. This protective effect of PROB may be related to the maintenance of the antioxidant status of the heart.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT
Lowry, O., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 317,331
Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase.
Paglia, D. E., & Valentine, W. N. (1967) · PubMed · Cited by 10,889
Handbook of methods for oxygen radical research
Greenwald, R. A. (1987) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(87)80012-6 · Cited by 2,381
Estimation of product of lipid peroxidation (malonyl dialdehyde) in biochemical systems
Placer, Z. A., Cushman, L. L., & Johnson, B. C. (1966) · Analytical Biochemistry · doi:10.1016/0003-2697(66)90167-9 · Cited by 2,328
A clinicopathologic analysis of adriamycin cardiotoxicity
Lefrak, E. A., Piťha, J., Rosenheim, S., & Gottlieb, J. A. (1973) · Cancer · doi:10.1002/1097-0142(197308)32:2<302::aid-cncr2820320205>3.0.co;2-2 · Cited by 1,560
Adriamycin: The Role of Lipid Peroxidation in Cardiac Toxicity and Tumor Response
Myers, C. E., McGuire, W. P., Liss, R. H., Ifrim, I., Grotzinger, K., & Young, R. C. (1977) · Science · doi:10.1126/science.877547 · Cited by 1,111
Cardiac Toxicity 4 to 20 Years After Completing Anthracycline Therapy
Steinherz, L. J. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03470120074036 · Cited by 989
Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous Infusion
LEGHA, S. S., BENJAMIN, R. S., MACKAY, B., EWER, M., WALLACE, S., VALDIVIESO, M., RASMUSSEN, S. L., BLUMENSCHEIN, G. R., & FREIREICH, E. J. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-96-2-133 · Cited by 763
Effect of anthracycline antibiotics on oxygen radical formation in rat heart.
Doroshow, J. H. (1983) · PubMed · Cited by 711
Subcellular effects of adriamycin in the heart: A concise review
SINGAL, P., DEALLY, C., & WEINBERG, L. (1987) · Journal of Molecular and Cellular Cardiology · doi:10.1016/s0022-2828(87)80392-9 · Cited by 465
Self-citationKalyanaraman, B., Perez-Reyes, E., & Mason, R. P. (1980) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/0304-4165(80)90142-7 · Cited by 317
Siveski-Iliskovic, N., Kaul, N., & Singal, P. K. (1994) · Circulation · doi:10.1161/01.cir.89.6.2829 · Cited by 265
Self-citationPryor, W. A., Strickland, T., & Church, D. F. (1988) · Journal of the American Chemical Society · doi:10.1021/ja00215a036 · Cited by 239
Electrolyte and morphologic alterations of myocardium in adriamycin-treated rabbits.
Olson, H. M., Young, D. M., Prieur, D. J., LeRoy, A. F., & Reagan, R. L. (1974) · PubMed Central · Cited by 237
Kaul, N., Siveski-Iliskovic, N., Hill, M., Slezak, J., & Singal, P. K. (1993) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/1056-8719(93)90008-3 · Cited by 199
Self-citationHearse, D. J. (1991) · PubMed · Cited by 185
Bristow, M. R., Sageman, W. S., Scott, R. H., Billingham, M. E., Bowden, R. E., Kernoff, R. S., Snidow, G. H., & Daniels, J. R. (1980) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-198009000-00002 · Cited by 171
Goorin, A. M., Chauvenet, A. R., Perez-Atayde, A. R., Cruz, J., McKone, R., & Lipshultz, S. E. (1990) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)81668-3 · Cited by 163
Myocardial adrenergic changes at two stages of heart failure due to adriamycin treatment in rats
Tong, J., Ganguly, P. K., & Singal, P. K. (1991) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1991.260.3.h909 · Cited by 129
Self-citationA relative deficit in antioxidant reserve may contribute in cardiac failure.
Singal, P. K., & Kirshenbaum, L. A. (1990) · PubMed · Cited by 121
Self-citationAntioxidant activity of probucol and its analogs in hypercholesterolemic Watanabe rabbits
Mao, S. J. T., Yates, M. T., Rechtin, A., et al. (1991) · Journal of Medicinal Chemistry · doi:10.1021/jm00105a046 · Cited by 116
Adriamycin-induced myocardial dysfunction in vitro is mediated by free radicals
Lee, V., Randhawa, A. K., & Singal, P. K. (1991) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1991.261.4.h989 · Cited by 113
Self-citationHerman, E. H., & Ferrans, V. J. (1981) · PubMed · Cited by 108
Singal, P. K., & Pierce, G. N. (1986) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1986.250.3.h419 · Cited by 105
Self-citationGupta, M., & Singal, P. K. (1989) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y89-250 · Cited by 69
Self-citationSpeyer, J. L., Green, M. D., Dubin, N., Blum, R. H., Wernz, J., Roses, D. F., Sanger, J. J., & Muggia, F. M. (1985) · The American Journal of Medicine · doi:10.1016/0002-9343(85)90395-x · Cited by 52
Phase I study of ICRF-187 using a daily for 3 days schedule.
Hoff, V., Howser, D. M., Bj, L., Holcenberg, J. S., Weiss, R. B., & Rc, Y. (1981) · PubMed · Cited by 45
Cited by
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,778
Doxorubicin-Induced Cardiomyopathy
Singal, P. K., & Iliskovic, N. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809243391307 · Cited by 1,845
Self-citationRole of oxidative stress in cardiovascular diseases
Dhalla, N. S., Temsah, R. M., & Netticadan, T. (2000) · Journal of Hypertension · doi:10.1097/00004872-200018060-00002 · Cited by 1,467
Rawat, P. S., Jaiswal, A., Khurana, A., Bhatti, J. S., & Navik, U. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111708 · Cited by 909
Doxorubicin-Induced Cardiomyopathy
Takemura, G., & Fujiwara, H. (2007) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2006.10.002 · Cited by 827
Metadata
- Authors
- Siveski-Iliskovic, N., Hill, M., Chow, D. A., & Singal, P. K.
- Venue
- Circulation
- Published
- 1995-01
- Volume
- 91
- Issue
- 1
- Pages
- 10-15
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2011012865
- Cited by
- 285
- References
- 27
- FWCI
- 10.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.